All News
Filter News
Found 809,159 articles
-
NanoTemper Technologies Launches Spectral Shift, a Breakthrough Technology That Changes the Game for Affinity-Based Screenings
3/24/2022
NanoTemper’s Dianthus instrument includes breakthrough Spectral Shift technology to handle the most challenging affinity-based screenings in drug discovery.
-
Arcus Biosciences Announces New Employment Inducement Grants - Mar 24, 2022
3/24/2022
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eleven new employees options to purchase a total of 30,950 shares of the Company’s common stock at an exercise price per share of $32.98, which was the closing price on March 23, 2022, and restricted stock units to acquire a total of 15,475 shares of the Company’s common stock.
-
Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates
3/24/2022
Erasca, Inc. reported financial results for the fiscal quarter ended December 31, 2021, and provided business updates.
-
Oxford Nanopore Technologies PLC Announces Nanopore Sequencing Profiles TB: Find Evaluation
3/24/2022
Oxford Nanopore announces positive evaluation of new method for rapid drug-resistant tuberculosis profiling
-
ScreenPro Continues to Increase Market Share in Covid Testing
3/24/2022
Although there have been several changes in the current Covid climate with restrictions being lifted, the virus is still present, making Covid testing crucial in the film and production industry.
-
Vanqua Bio to Present at the Stifel 2022 CNS Day Conference
3/24/2022
Vanqua Bio today announced that the company will participate in the Stifel 2022 CNS Day Conference, which is being held virtually March 28-29.
-
Neurocrine Biosciences to Present Data from Movement Disorder Portfolio at the American Academy of Neurology 2022 In-Person and Virtual Annual Meeting
3/24/2022
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders program and telemedicine research at the American Academy of Neurology (AAN) Annual Meeting being held in person April 2–7, 2022 in Seattle and virtually April 24–26.
-
SK life science to Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Academy of Neurology 2022 Annual Meeting
3/24/2022
SK life science will share four posters and two oral presentations on its anti-seizure medication (ASM) cenobamate.
-
INVO Bioscience to Exhibit at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting
3/24/2022
INVO Bioscience, Inc. is exhibiting the INVOcell solution at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting, taking place March 23-27 at the Renaissance Esmeralda Resort & Spa.
-
Sun Pharma to Present Clinical Data Abstracts for ILUMYA® (tildrakizumab-asmn) in Patients with Moderate-to-Severe Plaque Psoriasis at 2022 AAD Annual Meeting
3/24/2022
Sun Pharmaceutical Industries Inc., USA (Sun Pharma) today announced that five data abstracts for ILUMYA will be presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting, taking place March 25-29.
-
LivaNova to Announce First-Quarter 2022 Results
3/24/2022
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m. London time (8 a.m. EDT).
-
Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
3/24/2022
Lineage Cell Therapeutics, Inc. today announced that Brian M. Culley, the Company’s Chief Executive Officer, will be presenting at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest.
-
Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting
3/24/2022
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that results from the pivotal Phase 3 RISE-PD clinical trial evaluating the novel investigational extended-release CD/LD formulation, IPX-203, in Parkinson’s disease patients with motor fluctuations, will be presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2-7, in Seattle, WA.
-
Blade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference
3/24/2022
Blade Therapeutics, Inc. today announced that the company will present data for cudetaxestat in three posters at the American Thoracic Society (ATS) 2022 International Conference, May 13-18, 2022, The Moscone Center, in San Francisco.
-
ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
3/24/2022
ProMIS Neurosciences, Inc. announced today that it will be presenting at the upcoming 10th Annual Neurodegenerative Drug Development Summit, to be held in Boston, MA, March 28-30, 2022.
-
Stealth BioTherapeutics Announces New Data on Complement Gene Expression and Cell Survival in Dry AMD to be Presented at ARVO (2022)
3/24/2022
Stealth BioTherapeutics Corp announced today the upcoming presentation of new data at The Association for Research in Vision and Ophthalmology (2022) Annual Meeting.
-
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31
3/24/2022
Taysha Gene Therapies, Inc. today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021, and host a corporate update conference call and webcast on Thursday, March 31, 2022, at 8:00 AM Eastern Time.
-
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
3/24/2022
Moderna today announced clinical and program updates demonstrating expansion and advancement of its mRNA pipeline.
-
Protalix BioTherapeutics to Hold Fiscal Year 2021 Financial and Business Results Conference Call on March 31, 2022
3/24/2022
Protalix BioTherapeutics, Inc. today announced that it will release its financial results for fiscal year 2021 and provide a business update on Thursday, March 31, 2022.
-
Calithera Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 31, 2022
3/24/2022
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s fourth quarter and full year 2021 financial results will be released on Thursday, March 31, 2022.